Insmed Inc logo

Insmed Inc

INSM
Healthcare|Biotechnology|USA
$115.61
-2.65 (-2.24%)
Tangible Book
$2.19

About

Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.

Stock Price

+19.6%(1Y)

Pipeline Summary

52 total trials
20
Phase 1
20
Phase 2
15
Phase 3
0
Phase 4
Terminated: 4Completed: 37AVAILABLE: 1APPROVED_FOR_MARKETING: 1Recruiting: 5NOT_YET_RECRUITING: 2Withdrawn: 1Active: 1

Active Trials (6)

A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)
NCT07481981Pulmonary Arterial Hypertension
Phase 3Recruiting
Enrollment: 344 participants
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
NCT07179380Pulmonary Hypertension
Phase 3Recruiting
Enrollment: 344 participants
A Study to Investigate the Safety and Pharmacodynamics of a Single Intrathecal Injection (IT) of INS1202 in Participants With Amyotrophic Lateral Sclerosis (ALS)
NCT07290062Amyotrophic Lateral Sclerosis
Phase 1Recruiting
Enrollment: 23 participants
An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)
NCT05649748Pulmonary Arterial Hypertension
Phase 2Phase 3Active
Enrollment: 91 participants
A Study to Investigate the Safety and Biodistribution of a Single Intrathecal (IT) Injection of INS1201 in Ambulatory Males With Duchenne Muscular Dystrophy (DMD)
NCT06817382Duchenne Muscular Dystrophy
Phase 1Recruiting
Enrollment: 12 participants
View all 6 active trials →

BioScore

5.9/10
Watchlist

Ownership

Recent Insider Trades

Lewis WilliamSELL
2026-07-0910,699 shares @ $117.4
Flammer Martina M.D.SELL
2026-07-0612,302 shares @ $109.98
Lewis WilliamSELL
2026-06-2521,398 shares @ $103.32
Smith Michael AlexanderSELL
2026-06-221,806 shares @ $95.82
Lewis WilliamSELL
2026-06-086,515 shares @ $94.03

Recent News

2026-07-10 13:08:37
2026-06-24 22:02:17
2026-06-23 12:00:04
2026-06-22 17:00:37
2026-06-15 11:33:55
Data last updated: Jul 12, 2026, 07:28 PM